Abstract: Increased understanding of the molecular mechanisms of tumor heterogeneity combined with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled studies on individualizing anticancer therapy. Doxorubicin (Adriamycin), is an anthracycline glycoside antibiotic originally produced by Streptomyces peucetius var. caesius, and is widely used either as a single agent or in combination with other chemotherapeutic regimens for curative, adjuvant, and palliative treatment in cancer patients. The pharmacogenetics of doxorubicin has not been well characterized. The polygenic influence of functional candidate gene variants across doxorubicin biochemical pathway is hypothesized to contribute to its heterogeneity in disposition, influencing the efficacy of treatment and occurrence of adverse effects like cardiomyopathy in patients undergoing doxorubicin based adjuvant and neo-adjuvant chemotherapy. The pharmacogenetics of Asian population differs from that of other ethnic groups, particularly from Caucasian and African populations, and indicates an important role of ethnicity in determining predictive end points during chemotherapy and in individualizing treatment.
INTRODUCTION
Breast cancer accounts for one third of all cancers in women and is the most prevalent cancer diagnosed among women around the world, occurring with a lifetime risk of one in eight [1, 2] . The incidence of breast cancer is continuously increasing, with more than 1,000,000 cases diagnosed each year worldwide [3, 4] . Detection of disease at an earlier stage and appropriate administration of systemic therapy in conjunction with conservative surgery and radiation has improved survival and decreased the morbidity and mortality of breast cancer patients [5] . Although the armamentarium of drugs available for the treatment of breast cancer is on the rise, the benefit from specific treatments to individual patients and the adverse effects experienced vary considerably depending on tumor, treatment and host characteristics. Nevertheless, it is now possible to individualize care based on the molecular variations within breast cancer. This has arisen from increased understanding of the biology of this heterogeneous disease and gives a greater impetus to further improve on the individualization of treatment.
Chemotherapy is an important modality in the management of patients with breast cancer complemented by radiotherapy and surgery. In the curative setting, it can be given as neo-adjuvant therapy or adjuvant therapy. Neoadjuvant therapy provides for tumor downstaging, allowing for either mastectomy in the case of inoperable disease, or breast conservation surgery [6] [7] [8] [9] [10] . It also provides a unique window to assess drug-tumor interaction, and in-vivo drug sensitivity in clinical trials. Moreover, pathological complete responses (pCR) to neoadjuvant chemotherapy predicts for better overall survival [11] . Adjuvant chemotherapy following primary tumor resection is aimed at eradicating micrometastatic disease [12, 13] . This translates to a survival benefit at 10 years of 4.5% and 11.3% in node negative and node positive women below the age of *Address correspondence to this author at the Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Centre, 11 Hospital Drive, Singapore 169610; Tel: (65) 6436 8321; Fax: (65) 6372 0161; E-mail: ctebal@nccs.com.sg 50 [14] , respectively, whereas in women aged 50 to 69, a smaller though still significant gain (3.2% and 3%, respectively) is observed [15, 16] . These benefits of adjuvant chemotherapy have been observed to be independent of the estrogen receptor (ER) status of the primary tumors and of the use of adjuvant tamoxifen [17] .
The Early Breast Cancer Trialist's Collaborative Group (EBCTCG) study summarized the results of all randomized adjuvant chemotherapy trials that began before 1990, concluding that combination chemotherapy in breast cancer improved long term relapse free and overall survival rates in women up to 70 years of age irrespective of nodal status or estrogen receptor (ER) status [16] . Combination chemotherapy that uses two or more drugs appeared to be superior to single agents; with four to six cycles of treatment (3-6 months) considered optimal [18] . The higher cell kill achieved due to non-overlapping toxicity of the component drugs and the tumor cell heterogeneity that vary in terms of drug sensitivity and resistance are considered important factors in the success of combination chemotherapy regimens. The combination of cyclophosphamide (C) with two antimetabolites, methotrexate (M) and fluorouracil (F) (CMF regimen), was established as the gold standard for adjuvant therapy of breast cancer in the mid 1970s [19, 20] .
The Early Breast Cancer Trialist's Collaborative Group (EBCTCG) study then performed an extended 15-year follow-up meta-analysis and showed that anthracycline containing regimens were significantly more effective at preventing recurrence (hazard ratio, 0.89; P = 0.001) and increasing survival (risk of breast cancer death rate ratio, 0.84; P < 0.00001), and had substantial advantages in terms of tolerability when compared to CMF regimen in the treatment of breast cancer [21, 22] . Three randomized trials (NCIC MA547, intergroup 0102/SWOG 88949 and NEAT/SCTBG Br960150) have clearly demonstrated the superiority of therapy with anthracycline-based regimens over CMF. The trends toward superiority of anthracycline-based chemotherapy regimens over CMF regimen extend to the major subsets of early breast cancer patients: premenopausal and postmenopausal patients, ER-poor and ER-positive patients, and both node-negative and node-positive patients [23] . Two randomized studies, National Surgical Adjuvant Breast and Bowel Project (NSABP-15 and NSABP-23) found that four cycles of doxorubicin/cyclophosphamide (AC) were equivalent to six cycles of conventional CMF with respect to event-free survival, relapse-free survival, and overall survival in breast cancer patients regardless of nodal status, age, or estrogen-receptor status [23] . Since AC regimen also offered the advantages of a shorter treatment course with fewer side effects, it has been readily adopted as a standard adjuvant regimen in breast cancer chemotherapy [24, 25] .
CLINICAL PHARMACOLOGY OF DOXORUBICIN
Doxorubicin, produced by a variant of Streptomyeces peucetius (var.caesius), is a nucleolar non-selective class I anthracycline that inhibits both DNA and nucleolar RNA synthesis at approximately equivalent concentrations. It has a wide spectrum of antitumor activity, and is widely used in the treatment of lymphomas, leukemia's, breast, lung, ovarian, gastric and thyroid malignancies [26] .
PHARMACOKINETICS OF DOXORUBICIN
Doxorubicin is approximately 50 to 80% bound to plasma proteins, and has a volume of distribution (V d ) ranging from 500 to 800 L/m 2 . The blood levels of doxorubicin fall rapidly as the drug distributes to tissues and the high tissue penetration and retention in nucleated cells has been attributed to its lipophilicity and DNA binding capacity. Doxorubicin has been shown to enter cells via passive diffusion, and intracellular accumulation result in concentrations that are 10-to 500-fold greater than extracellular levels. Intracellularly, nuclear concentrations of doxorubicin are 50-fold higher than in the cytoplasm (reaching 340 uM at saturation) representing one molecule intercalated every 5 base pairs of DNA [27, 28] whereas free doxorubicin is very low (0.2% of the total intracellular drug) and heterogeneously distributed due to sequestration in organelles such as lysosomes, mitochondria and Golgi apparatus [29, 30] . The highest accumulation of doxorubicin among tissues is seen in the liver, while white blood cells and the bone marrow concentrates doxorubicin at 200 to 500 fold higher levels than in the plasma. Doxorubicin does not cross the blood brain barrier.
The biotransformation of doxorubicin occurs primarily in the liver, by the stereo-specific reduction of the ketone on the C-13 yielding doxorubicinol, a 13-dihydroderivative with a hydroxyl moiety (Fig. (1) ). This is carried out by the ubiquitious cytoplasmic carbonyl reductase and aldo-keto reductase metabolizing enzymes. Subsequent metabolism of both doxorubicin and doxorubicinol involves reductive and hydrolytic glycosidic cleavage, Odemethylation, O-sufation, and O-glucuronidation. The acidcatalysed hydrolysis of the glycosidic bond eliminates the sugar component to derive doxorubicinone from doxorubicin and doxorubicinolone from doxorubicinol. The reductive removal of the C7-linked daunosamine sugar group via a semi-quinone intermediate and subsequent protonation of the C7-aglycone radical produces 7-deoxydoxorubicinone from doxorubicin and 7-deoxydoxorubicinolone from doxorubicinol. These insoluble 7-deoxyaglycones after demethylation require conjugation with glucuronic or sulphonic acid for excretion. Doxorubicin aglycones have been detected in the biological fluid of only some patients undergoing treatment, and occur only transiently and at very low concentrations compared with doxorubicin and doxorubicinol [31] . Doxorubicin hydroquinone production by the two-electron reduction of the quinone moiety by NAD(P)H-quinone oxidoreductase has been proposed but has not yet been detected in biological specimens [32] [33] [34] .
Doxorubicin clearance is predominantly mediated by the hepatobiliary pathway, with more than 50% of the drug excreted in bile within 7 days after treatment. About 10 to 20% and 40 to 50% of the dose is excreted in faeces within 24 and 150 hours, respectively.
Renal clearance of doxorubicin is low, and about 12% of total dose is recovered in the urine during 6 days after treatment. Intravenous infusion of doxorubicin is followed by a triphasic plasma clearance characterized by three successive half lives (t : 3 to 5 minutes, t : 1 to 2 hours, t : 24 to 36 hours). A fourth half life (t of 110 hours), representing up to 30% of the total area under the plasma concentration-time curve (AUC 0-) has also been reported. The plasma concentration of doxorubicinol rapidly increases and then decreases parallel to that of doxorubicin, following bolus injection of the parent drug. During instances of prolonged infusion of doxorubicin, the concentration of doxorubicinol might exceed that of doxorubicin, and the ratio of the AUC 0-of doxorubicinol to the AUC 0-of doxorubicin may exceed 1. Doxorubicinol contributes to 23% of biliary excretion whereas the remainder consists of other metabolites. A rebound of plasma concentrations of doxorubicinol has been observed 4-8 hours after doxorubicin administration suggesting the existence of an entero-hepatic recirculation [29] .
PHARMACODYNAMICS OF DOXORUBICIN
The pharmacodynamics of doxorubicin results from its cytotoxic and antiproliferative effects, attributed to its action on multiple molecular targets including key cellular enzymes such as topoisomerases I and II [35] . Topoisomerase II mediated DNA damage by doxorubicin is followed by G1 and G2 growth arrest and induction of apoptosis, and has been proposed to correlate with tumor response and patient's outcome [31] . Other pharmacodynamic effects of doxorubicin at the cellular level include intercalation of doxorubicin into DNA leading to the inhibition of the synthesis of macromolecules and generation of free radicals that results in DNA damage or lipid peroxidation, DNA binding and alkylation, DNA cross-linking, interference with DNA unwinding or DNA strand separation, helicase activity and direct membrane effects [36, 37] . Due to its mechanism of action and toxicity, clinical or biochemical pharmacodynamic endpoints rather than molecular alterations are often used as surrogates to monitor efficacy of doxorubicin based chemotherapy.
Relationship between the pharmacokinetics of doxorubicin, cytotoxicity and clinical outcomes have been established in several studies [38, 39] . Increase in peak plasma concentrations (Cmax) of doxorubicin has been correlated to increased incidence of cardiotoxicity [40] and post-infusion plasma steady state levels (Css) of doxorubicin have also been associated with the relative nadir of white blood cell count that follows doxorubicin administration [41] . Factors contributing to the variability in the biochemical and clinical pharmacodynamic outcomes following doxorubicin administration may be attributed to tumor heterogeneity, preexisting physiological conditions as well as variations related to dosing schedules of doxorubicin and its associated pharmacokinetics, genetics, age, prior chemotherapy or radiation therapy, poor performance status, co-morbid disease states, and co-medications [41] . The phenomenon of pharmacodynamic tolerance that relates to doxorubicin induced changes in receptor density or efficiency of receptor coupling to signal transduction pathways is also important and needs to be taken into consideration while interpreting the pharmacodynamics of doxorubicin.
PHARMACOGENETIC FACTORS AFFECTING DOXORU-BICIN DISPOSITION
Aside from variations at the level of the tumor, the factors influencing the disposition of doxorubicin and mechanisms determining efficacy of treatment during breast cancer chemotherapy are also influenced by the action of various influx and efflux transporters that are responsible for its translocation across cellular membranes, as well as the drug metabolizing enzymes which are responsible for its biotransformation (Fig. (2) ). Recent in-vitro and in-vivo studies have demonstrated the significant roles of these proteins in affecting the intracellular levels of doxorubicin and doxorubicinol [42] [43] [44] . Genetic factors have been suggested to account for 20-95% of the observed inherited variability in therapeutic efficacy and toxicity of drugs in individual patients [45, 46] . Pharmacogenetic studies in breast cancer patients may provide critical insights regarding variability in response and/or toxicity to doxorubicin based adjuvant and neo-adjuvant chemotherapy regimens and mechanisms of resistance to treatment. In addition, several of the key drug transporters and metabolizing enzymes are now known to be under transcriptional control by regulatory genes such as the orphan nuclear receptors encoding genes. With regards to pharmacogenetic factors affecting the pharmacokinetics and pharmacodynamics of doxorubicin, the genes encoding the efflux transporters (ABCB1, ABCB5, ABCB8, ABCC5, ABCG2, RLIP76), influx transporter (SLC22A16), drug metabolizing enzymes (CBR1 and CBR3) and the orphan nu-clear receptor, PXR, have been implicated. These genes are polymorphic and understanding their polygenic interaction across the doxorubicin biochemical pathway is important in delineating the causes of interpatient variability in the pharmacokinetics and pharmacodynamics of doxorubicin. The contribution of pharmacogenetic factors across the doxorubicin biochemical pathway is not well characterized and it is important to understand their contributory roles so as to gain a better insight with regards to the mechanistic basis of interpatient as well as interethnic differences in its disposition characteristics of doxorubicin.
ROLE OF EFFLUX TRANSPORTERS IN INFLUENCING DOXORUBICIN DISPOSITION ABCB1
The multi drug transporter efflux ABCB1 (MDR1) is a member of the ABC subfamily class B, encoding for the P-glycoprotein (Pgp), and is the best characterized ABC transporter since its isolation in 1976 [47] . The ABCB1 gene, containing 27 exons (6-204 bp) and spanning over 209 kb, is located on chromosome 7q21-31 and encodes a 1280 amino acid polypeptide (170kDa) [48] . Human ABCB1 is a phosphorylated and glycosylated protein consisting of 12 hydrophobic TMDs and 2 NBDs. One NBD connects two TMDs with a hydrophilic NBD loop; the TMDs form channels for the efflux of substrate drugs whereas NBDs located in the interior of cytoplasm participate in ATP binding and hydrolysis [49] . ABCB1 is localized in the plasma membrane, in the apical/luminal membrane in polarized cells and is also present in the brush border membrane of intestinal cells, the biliary canalicular membrane of hepatocytes, the luminal membrane of proximal tubule epithelial cells of the kidney, and in the endothelial cells at the blood-brain barrier.
Several in-vitro studies have identified ABCB1 as a major candidate mediating doxorubicin resistance [50] [51] [52] [53] [54] . Drug resistant cell lines treated with ABCB1 siRNA display increased intracellular doxorubicin accumulation, leading to increased doxorubicin sensitivity and 12-fold reversal of resistance [54] . The breast cancer Hs578T-Dox cell line overexpressing ABCB1 is approximately 200 times less sensitive to doxorubicin when compared to non-ABCB1 expressing Hs578T cells [54] . Treatment with ABCB1 inhibitors such as carvedilol and verapamil reduce the LD50 for doxorubicin in Hs578T-Dox cells while only marginally affecting the cytotoxicity of Hs578T cells. The expression of ABCB1 has also been shown to be rapidly upregulated by treatment with anthracyclines. In a study by Neilsen et al [55] approximately 75% of the various cell lines made resistant by exposure to anthracyclines exhibited a complete multidrug resistant phenotype.
The possible influence of ABCB1 on doxorubicin disposition has been investigated in several studies. Doxorubicin elimination into the intestinal lumen by ABCB1 expressed in the intestinal epithelium has been proposed to play a role in the poor oral bioavailability of doxorubicin [56] . In-vivo studies with ABCB1 inhibitors such as PSC-833 showed marked inhibition of biliary secretion of doxorubicin, probably by blocking ABCB1 mediated transport in the hepatocyte canaliculus [57] . Studies in mdr1a knockout mice that lacked expression of the murine ABCB1 isoform [58] also support the role of ABCB1 in doxorubicin elimination via hepatic and extra hepatic mechanisms [58] . The increased hepatic and renal expression of ABCB1 in response to doxorubicin exposure suggest that the alterations in doxorubicin pharmacokinetics observed in multiple treatment regimens may be related to the induction of ABCB1 in hepatic and extrahepatic tissues [59] .
At least 105 ABCB1 single nucleotide polymorphisms (SNPs) have been reported to date, the majority being located either in the noncoding or intronic regions [60] . However, majority of studies on genotype related function of ABCB1 have investigated three high frequency variants in exons 12, 21 and 26 in relation to altered disposition of its putative drug substrates. Studies have since highlighted the strong linkage disequilibrium associated with ABCB1 polymorphisms at exons 12, 21 and 26 and identified haplotypes revealing ethnicity specific patterns [60] [61] [62] . Homozygosity for the variant forms at the three loci have been associated with reduced ABCB1 activity and higher exposure levels of ABCB1 drug substrates [62] [63] [64] [65] .
Recent studies from our laboratory have reported on the contributions of ABCB1 polymorphisms on the pharmacokinetics of doxorubicin and doxorubicinol by analyzing the composite genotype information from the ABCB1 1236-2677-3435 loci [66] . The CC-GG-CC genotype constitution was associated with lower exposure levels and increased clearance of doxorubicin when compared to the subjects harboring the TT-TT-TT genotype. The observation of reduced peak plasma concentrations of doxorubicin in these subjects who were homozygous for the reference allele at all the three loci is similar to our previously published reports on the influence of ABCB1 haplotypes on cyclosporine levels [62] . These findings are consistent with the view that the three tightly linked ABCB1 polymorphisms at exons 12, 21 and 26 are probably responsible for affecting its transport functions. However, the possibility of doxorubicin disposition being subject to influence by other ABCB1 polymorphisms that have been shown to be the part of an important haplotype structures in different populations remains to be investigated [60] .
ABCB5
ABCB5 [subfamily B (MDR/TAP), member 5] is a novel human ABC transporter and its designation was based on its similarity in sequence homology to other ABCB family members, ABCB1 and ABCB4 [67] . The human ABCB5 gene consists of 16 exons and spans over 108 kb, is located on chromosome 7p15 and encodes an 812 amino acid polypeptide (92 kDa). It has been hypothesized that ABCB5, similar to ABCB1, functions as a drug resistance mediator in human cancer cells [68] . Assessment of the role of ABCB5 in cellular drug transport and chemoresistance to doxorubicin in ABCB5-expressing human G3361 melanoma cells showed that the cells are heterogeneous with regard to initial intracellular doxorubicin accumulation, with a distinct subpopulation (7.2%) of cells exhibiting high doxorubicin uptake on drug incubation. When ABCB5 expression and doxorubicin content were assayed concurrently, it was found that 80% of ABCB5 expressing tumor cells exhibited the doxorubicin-high phenotype. In contrast, neither doxorubicin-high nor doxorubicin-low G3361 melanoma cells expressed ABCB1. The ABCB5 expressing cells accumulated significantly less doxorubicin (up to 52% reduced accumulation at 24 hours) during all exposure times tested compared with melanoma cells that did not express ABCB5 [68] . Reduction in ABCB5 mRNA levels by using siRNA induced drug sensitivity to several drugs including camptothecin, 5-FU, and mitoxantrone, implying that elevated ABCB5 expression may confer drug resistance to anticancer agents, including doxorubicin [69] . Two isoforms of the protein ABCB5alpha and ABCB5beta have been reported in melanoma and melanocytes [70] . ABCB5alpha is an alternative splice variant and ABCB5beta shares 70% homology with ABCB1. They are pigment cell specific and not described in other normal tissue or breast cancer. The therapeutic implications of these isoforms in relation to doxorubicin pharmacology are unknown.
To date, there are no reports on the pharmacogenetics of ABCB5. Preliminary screening in Asian healthy subjects by direct sequencing of the coding regions of the ABCB5 gene identified three novel polymorphisms (unpublished data). All polymorphisms were non-synonymous transitions: c.2T>C (exon 1), c.343A>G (exon 2) and c.1573G>A (exon 12) polymorphisms that resulted in the p.M1T, p.K115E and p.E525K amino acid changes, respectively. The genotypic frequency of the heterozygous c.2T>C polymorphism was almost two-fold higher in the healthy Indian (23%) population compared with the Chinese (8%) and Malay (10%) populations. The frequency of the c.2C variant allele was also significantly higher among Indians (0.12) when compared to Chinese (0.05, P = 0.007) and Malays (0.04, P = 0.026). The allele frequency distribution of ABCB5 c.343A>G and c.1573G>A polymorphisms did not differ significantly between healthy ethnic groups. Among cancer patients, the allele frequency of the c.343A>G variant allele was found to be significantly lower (0.05) when compared to the healthy Chinese subjects (0.14) while the genotype and allele frequencies of the ABCB5 c.2T>C and c.1573G>A polymorphisms conformed to the frequencies found among the local population from which they were recruited. The clinical impact of these polymorphisms is unknown and deserves further investigations.
ABCB8
ABCB8 [subfamily B (MDR/TAP, member 8]), an ATPdependent efflux transporter, is a member of the ATP-binding cassette (ABC) transporter superfamily [71] . The human ABCB8 gene is located on chromosome 7q36 and consists of 16 exons and spans over 19 kb [72] . Unlike ABCB5, the ABCB8 protein is a halfmembrane transporter, consisting of one transmembrane domain with a single ATP-binding site. Hence, homodimerization of ABCB8 is required for its activity [71] . ABCB8 is localized in the inner mitochondrial membrane, and is thought to play a role in iron metabolism as well as transport of iron/sulphur protein precursors [71] . As a member of the multidrug resistance (MDR) transporter associated with antigen processing (TAP) (MDR/TAP) subfamily, ABCB8 has been hypothesized to play a vital role in extruding chemotherapeutic drugs from cancer cells and displaying the multidrug resistance phenomenon [73] . A recent microarray analysis demonstrated a higher expression of various ABC transporters, including ABCB8, in doxorubicin-resistant human T-lymphoblastoid leukemic cells in comparison to doxorubicin-sensitive parental line, suggesting a possible role of ABCB8 in doxorubicin chemoresistance [50] . In addition, Elliot et al [74] illustrated that ABCB8 knockdown with shRNA reduced doxorubicin resistance in melanoma cell lines, and this effect was doxorubicin-specific when compared to other chemotherapeutic drugs.
Previously, screening of ABCB8 gene in the Japanese population by Saito et al [75] identified 21 genetic polymorphisms. However, the frequency data was not reported. Recent preliminary screening in Chinese, Malay, Indian and Japanese subjects in our lab has identified a total of 61 SNPs (21 were eliminated because allele frequencies are <1%), where 30 are novel (unpublished data) (Fig. (3) ). The majority of the SNPs are located in the intronic region. Among the 8 exonic SNPs found, six result in nonsynonymous transitions:
(p.S560C) and c.2129G>A (p.G710V). To date, the influence of these genetic polymorphisms on pharmacokinetics of candidate drug substrates such as doxorubicin is unknown, and this warrants further investigation.
ABCC5
ABCC5 [Canalicular multispecific organic anion transporter C, MRP5/ABC33] was originally classified as an organic anion transporter and belongs to ABCC subfamily, one of the largest subfamilies of the ATP-binding cassette (ABC) transporters. The human ABCC5 gene consists of 29 exons and spans over 98 kb, is located on chromosome 3q27 and encodes a 1437 amino acid polypeptide (190kDa) (Fig. (4) ). ABCC5 belongs to the short type of ABCC proteins that differ from the long type by the lack of an N-terminal transmembrane domain. Sequence analyses predict that ABCC5, similar to other ABC transporters, contains the Walker A, B and C Fig. (3) . Graphical representation of SNPs found in ABCB8 gene. motifs, nucleotide binding folds, and 12 transmembrane spanning helices in 2 hydrophobic domains [76] . In transfected epithelial cells, ABCC5 was found to localize to the basolateral membrane [77] . ABCC5 displays wide tissue distribution such as the smooth muscle cells of the human genito-urinary tract [78] in the basal membrane of syncytiotrophoblasts and in fetal vessels [79] and in cardiomyocytes and endothelial cells [80] .
ABCC5 has been reported to confer resistance to several drugs including methotrexate, and the thymidilate synthase inhibitor raltitrexed [81] . Pratt et al [82] suggested that ABCC5 mediated transport of 5-fluorouracil may contribute to resistance in breast cancer patients. In the same study, the investigators showed that ABCC5 transfectants demonstrated a two-fold resistance to doxorubicin. Park et al [83] analyzed ABCC5 transporter gene expression profiles in breast cancer patients who underwent sequential weekly paclitaxel/FEC (5-fluorouracil, epirubicin and cyclophosphamide) neo-adjuvant chemotherapy. Significantly higher expression of ABCC5 was observed in the residual disease group, along with ABCA12, ABCA1, ABCC13, ABCB6 and ABCC11. Analysis of ABCC5 mRNA levels in doxorubicin resistant cells showed elevated ABCC5 expression suggesting major roles of ABCC5 in mediating doxorubicin resistance [84] . Screening the ABCC5 gene in Caucasian patients suffering from cardiomyopathy identified twenty polymorphisms among which five polymorphisms were in the putative promoter region, four synonymous polymorphisms in the exonic regions and two polymorphisms in the 3'-UTR region [74] . No significant associations of ABCC5 polymorphisms with gene expression were observed. However, Saito et al. [85] sequenced the entire ABCC5 gene and its 3'-flanking region in 48 unrelated Japanese individuals and identified 85 polymorphisms. Gwee PC et al. [86] sequenced the entire length of the ABCC5 gene and observed 130 different ABCC5 haplotypes in five populations (Chinese, Malays, Indians, Caucasian and African-Americans). Similarities in ABCC5 haplotype profiles were observed between the Chinese and Malays and between the Caucasians and Indian ethnic groups. Significant strong linkage was observed between the intron 1 -1205C>T and intron 30 c.7161G>A polymorphisms that are separated by more than 100 kb in the ABCC5 gene, suggesting that the entire ABCC5 gene resides within a region of strong linkage disequilibrium. The genotypic influence of these polymorphisms on pharmacokinetics of candidate drug substrates such as doxorubicin is unknown.
Ral-Binding Protein 1; RALBP1 (RLIP76)
RLIP76 (Ral-Binding Protein 1, 76-KD) is an ATP dependent non-ABC multispecific transporter protein, initially predicted to be involved in regulation of membrane plasticity, movement, and endocytosis. The human RLIP76 gene, consisting of 9 exons and spanning over 62 kb, is located on chromosome 18p11.3 and encodes a 655 amino acid polypeptide (76 kDa) [87] . The mechanism of transport by RLIP76 appears to be through interaction with the membrane by antennapedia-homeodomain homologous sequences within the N-terminal, coupled with ATP-hydrolysis simulated by substrate binding [88] . The C-terminal domain has been shown to bind Reps-1 and polymerase-protein (POB1) linking RLIP76 to epidermal growth factor receptor (EGFR), insulin receptor and transforming growth factor-(TGF ) receptor [89, 90] . The sequence of the ATP-binding sites in N terminal (69GKKKGK74) and C terminal domain (418GGIKDLSK425) of RLIP76 is similar with the consensus for the P-loop (Walker motif) in the ABC transporter proteins, but unlike the ABC transporters, no transmembrane helices are evident in the RLIP76 sequence [91] .
Awasthi et al. [92] identified RLIP76 to be involved in the energy-dependent efflux of structurally unrelated amphiphilic compounds such as doxorubicin. Incorporation of purified RLIP76 into erythrocyte inside out vehicles (IOVs) doubled the rate of doxorubicin transport. RLIP76 stimulated ATP hydrolysis in the presence of weakly cationic drugs (doxorubicin and dihydrodoxorubicin) and its uncharged metabolites (doxorubicinone, deoxydoxorubicinone, and dihydrodoxorubicinone) showing that the RLIP76 protein may be involved in the protection of cells against the toxic effects of amphiphilic toxins as well as their phase I and II biotransformation products. Physiological significance of the ATP-dependent transport of doxorubicin by RLIP76 was further confirmed by transfection experiments where RLIP76-overexpressing cells showed increased efflux of doxorubicin and acquired resistance to both doxorubicin and hydroxynonenal (4-HNE) [93] . These observations combined with its ability to transport substances such as leukotrienes [94] and its ubiquitous expression in human tissues indicate that transport by RLIP76 may have toxicological as well as physiological relevance.
The wide tissue distribution and ability to transport doxorubicin with a Km in the range of clinically achievable serum doxorubicin concentrations suggest that the RLIP76 mediated transport mechanisms may be important in protecting normal or malignant tissues from doxorubicin toxicity. RLIP76 inhibition induces apoptosis in the absence of doxorubicin while synergistically enhancing cytotoxicity through increased cellular accumulation of the drug [95] . Consistent with these findings, augmentation of RLIP76 conferred protection of cells from doxorubicin cytotoxicity and resistance to apoptosis through increased doxorubicin efflux and reduced cellular doxorubicin accumulation [96] .
There have been few studies that investigated polymorphisms in the RLIP76 gene. Nineteen polymorphisms in the entire RLIP76 gene obtained from the HapMap project and 6 tagged polymorphisms were investigated in a report associating RLIP76 with predisposition to epilepsy [97] . Neither individual RLIP76 polymorphisms nor their haplotypes revealed any significant associations with clinical outcomes in the study. Further studies are required to identify the functional RLIP76 polymorphisms if any, in different population groups, including the functional roles. Given the estab- Fig. (4) . Graphical representation of SNPs found in ABCC5 gene.
lished role of RLIP76 in doxorubicin transport and mediating doxorubicin resistance, and the lack of data on the pharmacogenetics of RLIP76 in Asian population, it is important to investigate the influence of RLIP76 polymorphisms on the pharmacokinetics and pharmacodynamics of doxorubicin in Asian cancer patients.
Influx Transporters (SLC22A16)
The solute carrier family (SLC) of transporters transport specific substrates, such as amino acids, oligopeptides, sugars, monocarboxylic acid, organic cations, anions, phosphates, nucleosides, metals and water soluble vitamins, and are assumed to play important roles in mediating the uptake of drugs and endogenous metabolites [98] .Approximately 300 solute carrier (SLC) genes have been cloned and grouped into 43 families [99] . Major cellular uptake carrier systems include organic anion transporters (OATP, solute carrier protein (SLC21A), organic cation transporters (OCT, SLC22A), concentrative nucleoside transporters (CNT, SLC28A), dipeptide transporters (PEPT, SLC15A), and monocarboxylate carriers (MCT, SLC28A) [100] . The OATPs [OATP-C (SLC21A6), OATP8 (SLCO1B3) and OATP-A (SLC21A3)] are the main drug carrier proteins supporting the sodium-independent hepatic uptake of a variety of organic anions and have broad and partly overlapping substrate specificity [100, 101] . The OCTs [hOCT1 (SLC22A1), hOCT2 (SLC22A2)] translocate a variety of organic cations with widely differing molecular structures (281) and are also able to translocate organic cations in an electrogenic manner across the plasma membrane in either direction, operating independently of Na+ and proton gradients [102, 103] . Most substrates translocated by the OCT transporters are organic cations and weak bases that are positively charged at physiological pH. Solute carrier family of transporters typically mediate uptake and chemosensitivity for hydrophilic anticancer drugs, with members of the SLC19 family (reduced folate carrier, RFC family), SLC28 and 29 families (CNT and ENT nucleoside transporters), SLC7A and 3A families (amino acid transporters) and SLC31A 47 (CTR copper transporter family) shown to be important determinants of chemosensitivity to anticancer agents [104] .
The organic cation transporter SLC22A16 is also known as organic cation transporter 6 (hOCT6), carnitine transporter 2 (hCT2), Fly-like putative transporter 2 (hFLIPT2), or organic cation-binding protein 1 (OKB1) [105] . The human SLC22A16 gene, consisting of 8 exons and spanning over 51.9 kb, is located on chromosome 6q21 and encodes a 577 amino acid polypeptide (65 kDa). SLC22A16 has 12 predicted alpha-helical transmembrane domains and one large extracellular loop between domains 1 and 2 [106] . SLC22A16 is known to transport L-carnitine, which is an essential cofactor of metabolism with definitive role in disease states [107, 108] . In-vitro mutagenesis studies in transporters of the SLC22A family have shown that domains 4, 8, 10 and 11 and possibly other additional domains determine the structure of substrate binding pockets [109, 110] . SLC22A16 is constitutively expressed in leukemic as well as a variety of cancer cell lines [42] , brain, kidney and the Sertoli and epithelial cells of the epididymal ducts in the testis [111] . Recent in-vitro studies in Xenopus oocytes expressing the SLC22A16 protein demonstrated a dose dependent and saturable kinetics with regards to influx of doxorubicin [42] . Studies with Jurkat cells overexpressing SLC22A16 showed them to be increasingly susceptible to the cytotoxic effects of doxorubicin, and this was postulated to result from the increased influx of the drug. These studies suggest that alterations in the expression and activity of SLC22A16 may have profound implications on pharmacokinetics and pharmacodynamics of doxorubicin in cancer patients.
There are limited reports on the influence of genetic polymorphisms in the SLC22A16 gene on the disposition of anticancer agents in cancer patients. A recent report from our laboratory identified four novel polymorphisms in the SLC22A16 gene in healthy Asian subjects [c.146A>G (exon 2); c.312T>C, c.755T>C (exon 4) and c.1226T>C (exon 5) [112] . Significant differences were noted in the genotype frequencies of the c.146A>G and c.1226T>C polymorphisms among the different ethnic groups. Genotypicphenotypic association analysis in Asian breast cancer patients revealed that patients carrying the 146GG genotype had significantly higher exposure levels to both doxorubicin and doxorubicinol compared to patients carrying either one or two reference allele, thereby suggesting that polymorphic variants in the SLC22A16 gene may contribute to interethnic as well as interpatient variations in the pharmacokinetics of putative drug substrates. However, the pharmacodynamic influence of this novel polymorphism is not known and warrants further investigation in a larger sample size. In-vitro functional characterization of these novel polymorphisms with regards to SLC22A16 mediated transport of doxorubicin would be useful in understanding the role of this influx transporter in influencing the pharmacokinetics and pharmacodynamics of doxorubicin and its metabolites as well as other potential drug substrates.
DRUG METABOLIZING ENZYMES Carbonyl Reductases
Carbonyl reductases (CBRs) are ubiquitously expressed monomeric NADPH dependent cytosolic enzymes that catalyze the reduction of several chemically diverse substrates such as aldehydes, ketones, quinones and other xenobiotics [113, 114] . Apart from cellular metabolism of endogenous compounds such as steroids and their role in drug detoxification, carbonyl reductases are also assumed to participate in apoptosis [115] , mutagenesis [116] , carcinogenesis [117] , drug resistance [118] and signal transduction [119] . Originally assumed to belong to the aldo-keto reductase family, the four carbonyl reductases (CBR1, CBR2, CBR3 and CBR4) are now assigned to the family of short chain dehydrogenases (SDRs), one of the largest protein families identified to date [120] . Carbonyl reductase 2 (CBR2) is not present in human tissues, and its gene has not been found in the human genome. The CBR4 gene is located on human chromosome 4 (4q32.3) and encodes a protein comprised of 237 amino acids, but its enzymatic properties and tissue distribution remains unknown [121] .
Carbonyl Reductase 1 (CBR1)
The human CBR1 gene, consisting of 3 exons and spanning over 3.1 kb, is located on chromosome 21 and encodes a 277 amino acid polypeptide (30 kDa) (Fig. (5) ) [122] . The CBR1 gene lacks a CAAT and TATA box and contains a GC rich island extending into the first exon, a structure characteristic of genes having a housekeeping function [119] . Some of the identified substrates of human CBR1 include endogenous compounds such as prostaglandins and steroids and drugs such as loxoprofen [123] , metyrapone [123] , haloperidol [124] , bromoperidol [125] , timirepone [126] , and doxorubicin [119] .
In-vitro studies have shown that genetic variations in CBR1 gene could have significant functional consequences. Substitution of highly conserved basic residues (Lys-15, Ala-37 and Arg 38) in the N-terminal of CBR1 by neutral or acidic residues showed reduction of enzyme kinetic parameters by order of several magnitudes, highlighting their significant role in coenzyme binding and catalysis [145] . Polymorphic variants in CBR1 have been reported earlier by different groups. Avramopolous et al [127] identified the CBR1 3'-UTR G>A transition for the linkage mapping of the carbonyl reductase gene on chromosome 21. However, the effect of the polymorphism on enzyme activity and tissue expression is not known. Gonzalez et al [44] reported the V88I (rs1143663), L73L (rs25678), A209A (rs20572) and V231V (rs2230192) polymorphisms by screening of the full length CBR1 cDNA samples isolated from liver donors. The non-synonymous V88I G>A polymorphism occurred at a low frequency among African-Americans (q = 0.014) and resulted in CBR1 isoforms with distinct kinetic and thermodynamic properties. The V88 isoform presented 50% higher Vmax values for the anthracycline daunorubicin and synthesized 47% higher levels of its C-13 alcohol metabolite daunorubicinol. Based on in-vitro studies, it was proposed that individuals with homozygous CBR1 88I genotype may exhibit a slower rate of synthesis of C-13 alcohol metabolites that may be associated with reduced risk of cardiotoxicity associated with anthracycline therapy. There have been limited studies to date on the influence of genetic polymorphisms in the CBR1 gene on the pharmacokinetics of doxorubicin in cancer patients. Lal et al [128] reported five polymorphisms (-48G>A, c.219G>C, c.627C>T, c.693G>A and +967G>A), in the Asian population and diplotype-phenotype analysis showed that patients carrying the CBR1 D1 diplotype (characterized by the presence of reference alleles at the c.627C>T and +967G>A loci) had significantly higher clearance and lower exposure levels of doxorubicin compared with patients carrying the CBR1 D2 diplotype constitution (characterized by the presence of variant alleles at the c.627C>T and +967G>A loci).
Carbonyl Reductase 3 (CBR3)
The CBR3 gene which contains 3 exons spanning a region of 11.2 kb has a 72% sequence similarity with CBR1 and is located 62 kb telomeric to the CBR1 gene (Fig. (6) ). The relative expression of CBR3 is much lower than CBR1 in most tissues [121] . Lakhman et al [129] identified a CBR3 V244M polymorphism positioned in a region critical for interactions with the NADP(H) cofactor, occurring at higher frequency among the Africans (q = 0.51) compared to Caucasians (q = 0.31). Kinetic experiments with the recombinant CBR3 protein variants using the prototypical carbonyl reductase quinine substrate menadione revealed that CBR3 M244 isoform has significantly higher Vmax than V244 isoform, although both had similar Km values. No phenotypic consequence of this polymorphism was identified in Asian breast cancer patients [128] . Examination of the influence of the major CBR3 haplotype and diplotype structures also failed to reveal any significant association with doxorubicin disposition in Asian breast cancer patients. Further studies are required to identify the influence CBR3 polymorphisms on the pharmacokinetics of doxorubicin and other putative drug substrates in other populations.
REGULATORY NUCLEAR RECEPTORS
Nuclear receptors comprise a family of ligand-activated transcription factors that include the steroid, retinoid and thyroid hormone receptors and are involved in transferring the stimuli of exogenous and endogenous compounds into cellular responses, regulating the expression of their target genes [130, 131] . Unliganded nuclear receptors typically reside in the cytoplasm, bound to transcriptional co-repressors that recruit specific histone deacetylasecontaining complexes [132] . The ligands for the nuclear receptors are small and lipophilic in nature, which either permits them to diffuse readily into cells or are subjected to uptake by specific transport mechanisms. The binding of a ligand to the LBD results in a conformational change in the AF-2 that disrupts interactions with transcriptional co-repressor proteins such as nuclear receptor co26 repressor (N-CoR) and silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) and permits interactions with transcriptional coactivator proteins such as the steroid receptor coactivator-1(SRC-1) family members [133] . Once in the nucleus, the ligand-receptor complex recruits coactivators and form homodimers or, in many cases, heterodimerize with the retinoid X receptor (RXR). These heterodimer complexes stimulate the expression of target genes by binding to short DNA sequence motifs, termed response elements located in the regulatory regions of target genes.
Pregnane-X-Receptor
The activation of PXR is initiated in the cytoplasm, where following exposure to ligands, heterodimers consisting of PXR and the retinoic acid receptor (RXR; NR2B) binds to nuclear receptor response elements in the target genes and induce their transcription. PXR regulates the expression of drug transporters such as adenosine triphosphate (ATP) binding cassette (ABC) superfamily of transporters [134] , organic anion transporter protein 2 (SLC21A6) [135] and multidrug resistance proteins (MRP1 and MRP2) [133, 135] as well as cytochrome P450 drug metabolizing enzymes [136, 137] , highlighting its role in influencing drug disposition. The PXR gene maps to chromosome 3 (3q12-q13.3), spans approximately 40 kb, encodes the human PXR (hPXR) mRNA consisting of nine exons containing 434 amino acids and has a molecular weight of 49.7 Current Drug Metabolism, 2010, Vol. 11, No. 1 123 kDa. Ten alternatively spliced forms of hPXR have been identified to date [138, 139] . Tissue specific examination has showed that human PXR mRNA is predominantly expressed in liver and small intestine, and to a lesser extent, in kidneys, lungs and breast [140] .
Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway
Efforts to identify PXR targets by in silico screening showed that approximately 281 genes involved in drug metabolism and 97 genes involved in drug transporters have putative PXR/RXR binding sites [141] . PXR has been well documented to influence the expression of ATP-binding cassette family B1 (ABCB1) and the cytochrome P-450 3A (CYP3A) genes. PXR binds to CYP3A4 together with RXR as a heterodimer to two ER6 (everted repeats of AG(G/T)TCA) in the CYP3A4 5'-upstream region and to DR-4 type response elements in the ABCB1 gene. ABCB1 expression is also known to be coordinated with expression of CYP3A4, with both gene products being induced by the same spectrum of drugs [142] . P-glycoprotein and CYP3A4 are co-localized in liver and intestine, serving as a coordinated system for the absorption, metabolism and disposition of many drugs. Functional polymorphisms in PXR gene (Fig. (7) ) may help explain variation in the response of many metabolizing enzymes and transporters to drugs that are PXR ligands, including mechanisms that induce target genes such as ABC transporters which count doxorubicin among its variety of substrates.
In the report by Sandanaraj et al. [143] , PXR genotypephenotype correlations were analyzed by haplotype association through network based analysis, assuming that constituent haplotypes has minimal intra-and large inter-variations due to their sequence similarities [144] . The PXR*1A and PXR*1C were associated with a significantly higher PXR hepatic mRNA expression when compared to PXR*1B. Examination of the association between PXR*1A, *1B and *1C haplotype clusters in relation to hepatic expression of CYP3A4 and ABCB1 mRNAs as well as the pharmacokinetics of doxorubicin in breast cancer patients showed that the PXR*1B haplotype cluster was associated with a significantly reduced hepatic mRNA expression of CYP3A4 and a trend towards statistical significance with regards to expression of ABCB1 compared with hepatic tissues carrying the non-PXR*1B haplotype constitution. The PXR genotype-phenotype relationships were further associated with decreased doxorubicin clearance in breast cancer patients harboring the PXR*1B haplotype compared Fig. (7) . Graphical representation of SNPs found in PXR gene. Fig. (8) . Pharmacogenetic-Pharmacokinetic-Pharmacodynamic correlations across the doxorubicin biochemical pathway.
with patients carrying the non-PXR*1B haplotype, suggesting that PXR genetic constitution or haplotypes may significantly influence the expression and activity of its downstream target genes and the disposition of its putative drug substrates such as doxorubicin. Furthermore, the relationship between reduced PXR expression associated with PXR*1B among Indians (19.4%) compared to the Malay (35%) and Chinese (28.7%) subjects may have further implications in studies on interethnic variability in the pharmacokinetics of doxorubicin reported in Asian ethnic groups.
CONCLUSION
Doxorubicin plays a central role in cytotoxic chemotherapy for breast cancer and other cancers such as sarcomas. The interindividual variation in doxorubicin metabolism may have implications on the toxicity and potentially efficacy of the drug, making it critical to understand the pharmacogenetics and pharmacokinetics of the drug. Ethnic variations in genetics also may impact on these endpoints across different world populations. Recent exploratory studies from our laboratory have shown that the polygenic influence of several functional polymorphic variants in genes across the doxorubicin biochemical pathway (PXR, ABCB1, ABCC5, SLC22A16 and CBR1) may significantly impact on the pharmacokinetics of doxorubicin (Fig. (8) ). The polygenic influence of these candidate genes may also potentially contribute to the interindividual and inter-ethnic variability in doxorubicin disposition and its clinical efficacy (Fig (8) ). It is conceivable that apart from the pharmacogenetic factors, variations in doxorubicin pharmacokinetics could also involve factors such as varying schedules of administration, and influences of other study subject covariates such as age, ethnicity and body surface area (BSA) that are likely to play significant roles. Further studies across populations are needed to generate robust doxorubicin-based phenotype-genotype datasets in order to be able to recognize the goals of individualizing doxorubicin therapy.
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